A 48 week, d/b [double-blind], d/d [double dummy], randomised, m/n [multinational], m/c [multicentre], 2 arm, p/g [parallel group] clinical study of fixed combination beclomethasone diproprionate + formoterol fumarate via PMDI [pressurised metered dose inhaler] with HFA-134a propellant vs budesonide + formoterol DPI [dry powder inhaler] vs formoterol DPI in stable severe COPD [chronic obstructive pulmonary disease]

Trial Profile

A 48 week, d/b [double-blind], d/d [double dummy], randomised, m/n [multinational], m/c [multicentre], 2 arm, p/g [parallel group] clinical study of fixed combination beclomethasone diproprionate + formoterol fumarate via PMDI [pressurised metered dose inhaler] with HFA-134a propellant vs budesonide + formoterol DPI [dry powder inhaler] vs formoterol DPI in stable severe COPD [chronic obstructive pulmonary disease]

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Mar 2007

At a glance

  • Drugs Beclometasone/formoterol; Budesonide; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top